Journal of thoracic disease · 2025
Comparison of robot-assisted and video-assisted thoracic sleeve lobectomy in non-small cell lung cancer: insights from a high-volume center.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Hu Shiqi, Zeng Xiaoping, Wan Shiyue, Wang Suyu, Zhou Qianxin, Shen Ziyun, Zhang Jing, Zhang Peng
Аннотация
BACKGROUND: Although minimally invasive sleeve lobectomy (SL) preserves lung function, it is a complex and demanding thoracic surgical technique. This study aimed to evaluate perioperative and long-term outcomes of robot-assisted thoracic surgery (RATS) versus video-assisted thoracic surgery (VATS) in patients with non-small cell lung cancer (NSCLC) undergoing SL, and explore the safety and feasibility of robot-assisted SL in patients following neoadjuvant therapy.
METHODS: A retrospective analysis was performed on a cohort of patients diagnosed with NSCLC who underwent minimally invasive SL at a high-volume center between December 2019 and February 2023. Demographic characteristics, perioperative outcomes, and survival rates were compared between the RATS and VATS groups.
RESULTS: The study enrolled 347 patients with NSCLC, 78 (22.5%) patients received RATS and 269 (77.5%) patients received VATS. In the overall cohort, the RATS group was associated with a greater number of dissected lymph nodes (18.0 vs. 16.0; P=0.048) and a lower conversion rate (6.4% vs. 18.2%; P=0.01) than the VATS group. The overall median follow-up for the entire cohort was 34 [interquartile range (IQR), 26-42] months, with 30 (IQR, 26-38) months in the RATS group and 35 (IQR, 25-44) months in the VATS group. The Kaplan-Meier survival curves showed no significant difference in overall survival and progression-free survival (P=0.68 and P=0.98, respectively) between the groups.
CONCLUSIONS: Robot-assisted SL shows comparable results to VATS group for perioperative and long-term tumor prognosis. For patients who have received neoadjuvant therapy, robot-assisted SL is a safe and feasible option.
METHODS: A retrospective analysis was performed on a cohort of patients diagnosed with NSCLC who underwent minimally invasive SL at a high-volume center between December 2019 and February 2023. Demographic characteristics, perioperative outcomes, and survival rates were compared between the RATS and VATS groups.
RESULTS: The study enrolled 347 patients with NSCLC, 78 (22.5%) patients received RATS and 269 (77.5%) patients received VATS. In the overall cohort, the RATS group was associated with a greater number of dissected lymph nodes (18.0 vs. 16.0; P=0.048) and a lower conversion rate (6.4% vs. 18.2%; P=0.01) than the VATS group. The overall median follow-up for the entire cohort was 34 [interquartile range (IQR), 26-42] months, with 30 (IQR, 26-38) months in the RATS group and 35 (IQR, 25-44) months in the VATS group. The Kaplan-Meier survival curves showed no significant difference in overall survival and progression-free survival (P=0.68 and P=0.98, respectively) between the groups.
CONCLUSIONS: Robot-assisted SL shows comparable results to VATS group for perioperative and long-term tumor prognosis. For patients who have received neoadjuvant therapy, robot-assisted SL is a safe and feasible option.